Influence of granisetron on thermoregulation during exercise in the heat

Aviation Space and Environmental Medicine

Volumn 67, Issue 5, 1996, Pages 453-457

  McLellan, T M ^a,b   Ducharme, M B ^a  

^a DEF AND CIV INST OF ENVIRON MED   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GRANISETRON; PLACEBO;

ADULT; ARTICLE; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXERCISE; GAS EXCHANGE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; SKIN TEMPERATURE; SWEATING; THERMOREGULATION; VOMITING;

ANTIEMETICS; BODY TEMPERATURE REGULATION; DOUBLE-BLIND METHOD; EXERCISE; GRANISETRON; HEAT; HUMANS; OXYGEN CONSUMPTION; SWEATING;

EID: 0029865919     PISSN: 00956562     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Aapro MS. Review of experience with ondansetron and granisetron. Ann Oncol 1993; 4(Suppl. 3):S9-14.
2. Bruning TA, Chang PC, Blauw GJ, Vermeij P, van Zwieten PA. Serotonin-induced vasodilation in the human forearm is mediated by the "nitric oxide-pathway": no evidence for involvement of the 5-myreceptor. J Cardiov Pharmacol 1993; 22:44-51.
3. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990; 26(Suppl. l):S33-6.
4. Colin J, Timbal J, Houdas Y, Boutelier C, Guiev JD. Computation of mean body temperature from rectal and skin temperatures. J Appl Physiol 1971; 31:484-9.
5. 3 receptor antagonists and anti-emetic mechanisms of action. Anti-Cancer Drugs 1992; 3:79-85.
6. Givoni B, Goldman RF. Predicting rectal temperature response to work, environment, and clothing. J Appl Physiol 1972; 32:812-22.
7. Hardy JD, Stolwojk JAJ Partitional calorimetry studies of man during exposures to thermal transients. J Appl Physiol 1966; 21:1799-806.
8. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy-a randomised study. Eur J Cancer 1993; 29A:1669-72
9. Johnson JM. Exercise and the cutaneous circulation. In- Holloszy JO, ed. Exercise and sport sciences reviews. Baltimore, MD: Williams and Wilkins, 1992; 20.59-98.
10. McLellan TM Work performance at 40°C with Canadian Forces biological and chemical protective clothing. Aviat Space Environ Med 1993; 64:1094-100.
11. McLellan TM, Jacobs I, Bain JB. Influence of temperature and metabolic rate on work performance with Canadian Forces NBC clothing. Aviat Space Environ Med 1993; 64:587-94.
12. McLellan TM, Ducharme MB, Bateman W A. Influence of ondansetron on thermoregulation during exercise in the heat wearing combat clothing Aviat Space Environ Med 1994; 65:35-40.
13. Mitchell JW, Nadel ER, Stolwijk JAJ. Respiratory weight losses during exercise. J Appl Physiol 1972; 32:474-6.
14. Montain SJ, Sawka MN, Cadarette BS, Quigley MD, McKay JM. Physiological tolerance to uncompensable heat stress: effects of exercise intensity, protective clothing, and climate. J Appl Physiol 1994; 77:216-22.
15. Ruff P, Paska W, Goedhals L, Pouillart P, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallelgroup study. Oncology 1994; 51:113-8.
16. Schvartz E, Click Z, Magazanik A. Responses to temperate, cold and hot environments and the effect of physical training. Aviat Space Environ Med 1977; 48:254-60.
17. Snellen JW. Mean body temperature and the control of thermal sweating. Acta Physiol Pharmacol Neerl 1966; 14:99-174.
18. Stephenson LA, Kolka MA. Acetylcholinesterase inhibitor, pyridostigmine bromide, reduces skin blood flow in humans. Am J Physiol 1990; 258:R951-7.
19. Stephenson LA, Kolka MA. Increased skin blood flow and enhanced heat loss in humans after niacin ingestion. Natick, MA. U.S. Army Research Institute of Environmental Medicine, 1994; USA-RIEM Technical Report No. T94-16.
20. Tabona MV. An overview on the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy. Eur J Cancer 1990; 26(Suppl. 1):S37-41.
21. 3 antagonist. Eur J Cancer 1990; 26(Suppl. l):S12-5.